Sign in
Stories
BMY Stock's Undervaluation
Share
Biogen's Q3 Report and Reata Acquisition
BlackBerry's Loss and Business Separatio...
Businesses Navigate Revenue Challenges a...
Allstate Surpasses Q1 Earnings Forecast
Analysts Cut Forecasts on CoStar Group
Assenagon Acquires AstraZeneca Stake
Overview
API
Bristol Myers Squibb (BMY) reported Q3 results with revenues meeting estimates, but underperformed the S&P 500. Despite the decline in stock value, BMY is considered undervalued at $50, trading at a lower multiple than its 2023 expected earnings.
Ask a question
How might the acquisition of Mirati Therapeutics by BMY influence its oncology portfolio and future performance?
How might the underperformance of Bristol Myers Squibb stock impact the company's future growth prospects?
What factors could be contributing to the decline in BMY's stock value despite its Q3 results?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Aug 2023
Sep 2023
Oct 2023
Coverage